Literature DB >> 19942922

Hematology: dasatinib regimens for patients with chronic myeloid leukemia.

François Guilhot1, Lydia Roy.   

Abstract

Although imatinib mesylate therapy has dramatically improved the prognosis of patients in the advanced phases of chronic myeloid leukemia, room for improvement remains. Tyrosine kinase inhibitors are undergoing evaluation as second-line therapy for patients with imatinib-resistant disease. Kantarjian et al. recently demonstrated that once-daily dasatinib 140 mg is well tolerated and achieves a high response rate.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19942922     DOI： 10.1038/nrclinonc.2009.160

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  9 in total

1.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

2.  Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

Authors:  Jorge Cortes; Philippe Rousselot; Dong-Wook Kim; Ellen Ritchie; Nelson Hamerschlak; Steven Coutre; Andreas Hochhaus; Francois Guilhot; Giuseppe Saglio; Jane Apperley; Oliver Ottmann; Neil Shah; Philipp Erben; Susan Branford; Prasheen Agarwal; Ashwin Gollerkeri; Michele Baccarani
Journal:  Blood       Date:  2006-12-21       Impact factor: 22.113

3.  Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

Authors:  Francois Guilhot; Jane Apperley; Dong-Wook Kim; Eduardo O Bullorsky; Michele Baccarani; Gail J Roboz; Sergio Amadori; Carmino A de Souza; Jeffrey H Lipton; Andreas Hochhaus; Dominik Heim; Richard A Larson; Susan Branford; Martin C Muller; Prasheen Agarwal; Ashwin Gollerkeri; Moshe Talpaz
Journal:  Blood       Date:  2007-01-30       Impact factor: 22.113

4.  Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

Authors:  Andreas Hochhaus; Hagop M Kantarjian; Michele Baccarani; Jeffrey H Lipton; Jane F Apperley; Brian J Druker; Thierry Facon; Stuart L Goldberg; Francisco Cervantes; Dietger Niederwieser; Richard T Silver; Richard M Stone; Timothy P Hughes; Martin C Muller; Rana Ezzeddine; Athena M Countouriotis; Neil P Shah
Journal:  Blood       Date:  2006-11-30       Impact factor: 22.113

5.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

Authors:  Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; Francois Guilhot; Charles A Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

6.  Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Susan O'brien; Gautham Borthakur; John Bruzzi; Reginald Munden; Jorge Cortes
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

7.  Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Authors:  Neil P Shah; Hagop M Kantarjian; Dong-Wook Kim; Delphine Réa; Pedro E Dorlhiac-Llacer; Jorge H Milone; Jorge Vela-Ojeda; Richard T Silver; H Jean Khoury; Aude Charbonnier; Nina Khoroshko; Ronald L Paquette; Michael Deininger; Robert H Collins; Irma Otero; Timothy Hughes; Eric Bleickardt; Lewis Strauss; Stephen Francis; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

8.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.

Authors:  Hagop Kantarjian; Jorge Cortes; Dong-Wook Kim; Pedro Dorlhiac-Llacer; Ricardo Pasquini; John DiPersio; Martin C Müller; Jerald P Radich; H Jean Khoury; Nina Khoroshko; M Brigid Bradley-Garelik; Chao Zhu; Martin S Tallman
Journal:  Blood       Date:  2009-04-15       Impact factor: 22.113

9.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

Authors:  Philipp le Coutre; Oliver G Ottmann; Francis Giles; Dong-Wook Kim; Jorge Cortes; Norbert Gattermann; Jane F Apperley; Richard A Larson; Elisabetta Abruzzese; Stephen G O'Brien; Kazimierz Kuliczkowski; Andreas Hochhaus; Francois-Xavier Mahon; Giuseppe Saglio; Marco Gobbi; Yok-Lam Kwong; Michele Baccarani; Timothy Hughes; Giovanni Martinelli; Jerald P Radich; Ming Zheng; Yaping Shou; Hagop Kantarjian
Journal:  Blood       Date:  2007-11-29       Impact factor: 22.113
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.